VP Clinical Pharmacology Modeling & Simulation - Oncology
GlaxoSmithKline
Sandra Visser is the global head Oncology Clinical Pharmacology M&S at GlaxoSmithKline. Her group supports the oncology portfolio from candidate selection through approval into post-marketing. Sandra received her PhD in quantitative pharmacology from Leiden University in The Netherlands. Since then, she has accumulated outstanding experience with application of translational quantitative pharmacology, clinical pharmacology, and pharmacometrics in drug discovery and drug development programs, across multiple therapeutic areas at AstraZeneca, Merck, and GlaxoSmithKline. Moreover, she continuously focuses on bringing the vision of model-informed drug discovery and development (MID3) to life within the industry as well as within the public domain through workshops and publications. Finally, she has served the American Society of Clinical Pharmacology and Therapeutics in multiple leadership roles and is chairing the Scientific Programming Committee for the 2022 Annual Meeting.
Disclosure information not submitted.
Tuesday, January 11, 2022
10:00 AM – 11:00 AM ET
Thursday, January 13, 2022
4:15 PM – 5:15 PM ET
Thursday, January 13, 2022
9:00 PM – 10:00 PM ET
Friday, January 14, 2022
2:15 PM – 2:20 PM ET
Wednesday, March 16, 2022
12:30 PM – 1:30 PM ET
Thursday, March 17, 2022
10:15 AM – 11:15 AM ET
Friday, March 18, 2022
3:45 PM – 4:55 PM ET
.png)